FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4226371129> ?p ?o ?g. }

• W4226371129 abstract "Patients with stage II to III breast cancer have a high recurrence rate. The early detection of recurrent breast cancer remains a major unmet need. Circulating tumor DNA (ctDNA) has been proven to be a marker of disease progression in metastatic breast cancer. We aimed to evaluate the prognostic value of ctDNA in the setting of neoadjuvant therapy (NAT).Plasma was sampled at the initial diagnosis (defined as before NAT) and after breast surgery and neoadjuvant therapy(defined as after NAT). We extracted ctDNA from the plasma and performed deep sequencing of a target gene panel. ctDNA positivity was marked by the detection of alterations, such as mutations and copy number variations.A total of 95 patients were enrolled in this study; 60 patients exhibited ctDNA positivity before NAT, and 31 patients exhibited ctDNA positivity after NAT. A pathologic complete response (pCR) was observed in 13 patients, including one ER(+)Her2(-) patient, six Her2(+) patients and six triple-negative breast cancer (TNBC) patients. Among the entire cohort, multivariate analysis showed that N3 classification and ctDNA positivity after NAT were independent risk factors that predicted recurrence (N3, hazard ratio (HR) 3.34, 95% confidence interval (CI) 1.26 - 8.87, p = 0.016; ctDNA, HR 4.29, 95% CI 2.06 - 8.92, p < 0.0001). The presence of ctDNA before NAT did not affect the rate of recurrence-free survival. For patients with Her2(+) or TNBC, patients who did not achieve pCR were associated with a trend of higher recurrence (p = 0.105). Advanced nodal status and ctDNA positivity after NAT were significant risk factors for recurrence (N2 - 3, HR 3.753, 95% CI 1.146 - 12.297, p = 0.029; ctDNA, HR 3.123, 95% CI 1.139 - 8.564, p = 0.027). Two patients who achieved pCR had ctDNA positivity after NAT; one TNBC patient had hepatic metastases six months after surgery, and one Her2(+) breast cancer patient had brain metastasis 13 months after surgery.This study suggested that the presence of ctDNA after NAT is a robust marker for predicting relapse in stage II to III breast cancer patients." @default.
• W4226371129 created "2022-05-05" @default.
• W4226371129 creator A5007822629 @default.
• W4226371129 creator A5009133503 @default.
• W4226371129 creator A5015847499 @default.
• W4226371129 creator A5019503356 @default.
• W4226371129 creator A5023784038 @default.
• W4226371129 creator A5032340945 @default.
• W4226371129 creator A5033613006 @default.
• W4226371129 creator A5044262630 @default.
• W4226371129 creator A5068170043 @default.
• W4226371129 creator A5078468272 @default.
• W4226371129 creator A5087411305 @default.
• W4226371129 creator A5090705552 @default.
• W4226371129 date "2021-11-12" @default.
• W4226371129 modified "2023-10-06" @default.
• W4226371129 title "Circulating Tumor DNA as a Predictive Marker of Recurrence for Patients With Stage II-III Breast Cancer Treated With Neoadjuvant Therapy" @default.
• W4226371129 cites W167359183 @default.
• W4226371129 cites W1830454849 @default.
• W4226371129 cites W1963791274 @default.
• W4226371129 cites W1978158433 @default.
• W4226371129 cites W2019607817 @default.
• W4226371129 cites W2034896935 @default.
• W4226371129 cites W2044702943 @default.
• W4226371129 cites W2051978340 @default.
• W4226371129 cites W2093829133 @default.
• W4226371129 cites W2096283457 @default.
• W4226371129 cites W2104641188 @default.
• W4226371129 cites W2108088675 @default.
• W4226371129 cites W2121110176 @default.
• W4226371129 cites W2125094267 @default.
• W4226371129 cites W2132388337 @default.
• W4226371129 cites W2140575188 @default.
• W4226371129 cites W2147415463 @default.
• W4226371129 cites W2161332321 @default.
• W4226371129 cites W2161574596 @default.
• W4226371129 cites W2235523093 @default.
• W4226371129 cites W2460179076 @default.
• W4226371129 cites W2529230088 @default.
• W4226371129 cites W2560367415 @default.
• W4226371129 cites W2560399414 @default.
• W4226371129 cites W2747939174 @default.
• W4226371129 cites W2754606968 @default.
• W4226371129 cites W2758252083 @default.
• W4226371129 cites W2792450080 @default.
• W4226371129 cites W2805773873 @default.
• W4226371129 cites W2807173852 @default.
• W4226371129 cites W2891579961 @default.
• W4226371129 cites W2921241162 @default.
• W4226371129 cites W2924412259 @default.
• W4226371129 cites W2939548416 @default.
• W4226371129 cites W2962976163 @default.
• W4226371129 cites W2964980115 @default.
• W4226371129 cites W2965356616 @default.
• W4226371129 cites W2965583450 @default.
• W4226371129 cites W2969524309 @default.
• W4226371129 cites W3001165546 @default.
• W4226371129 cites W3010302436 @default.
• W4226371129 cites W3025589456 @default.
• W4226371129 cites W3038370630 @default.
• W4226371129 cites W3049233949 @default.
• W4226371129 cites W3109124091 @default.
• W4226371129 cites W3134153339 @default.
• W4226371129 doi "https://doi.org/10.3389/fonc.2021.736769" @default.
• W4226371129 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34868925" @default.
• W4226371129 hasPublicationYear "2021" @default.
• W4226371129 type Work @default.
• W4226371129 citedByCount "12" @default.
• W4226371129 countsByYear W42263711292022 @default.
• W4226371129 countsByYear W42263711292023 @default.
• W4226371129 crossrefType "journal-article" @default.
• W4226371129 hasAuthorship W4226371129A5007822629 @default.
• W4226371129 hasAuthorship W4226371129A5009133503 @default.
• W4226371129 hasAuthorship W4226371129A5015847499 @default.
• W4226371129 hasAuthorship W4226371129A5019503356 @default.
• W4226371129 hasAuthorship W4226371129A5023784038 @default.
• W4226371129 hasAuthorship W4226371129A5032340945 @default.
• W4226371129 hasAuthorship W4226371129A5033613006 @default.
• W4226371129 hasAuthorship W4226371129A5044262630 @default.
• W4226371129 hasAuthorship W4226371129A5068170043 @default.
• W4226371129 hasAuthorship W4226371129A5078468272 @default.
• W4226371129 hasAuthorship W4226371129A5087411305 @default.
• W4226371129 hasAuthorship W4226371129A5090705552 @default.
• W4226371129 hasBestOaLocation W42263711291 @default.
• W4226371129 hasConcept C121608353 @default.
• W4226371129 hasConcept C126322002 @default.
• W4226371129 hasConcept C143998085 @default.
• W4226371129 hasConcept C146357865 @default.
• W4226371129 hasConcept C151730666 @default.
• W4226371129 hasConcept C182516595 @default.
• W4226371129 hasConcept C207103383 @default.
• W4226371129 hasConcept C2778292576 @default.
• W4226371129 hasConcept C2781335228 @default.
• W4226371129 hasConcept C31258907 @default.
• W4226371129 hasConcept C38180746 @default.
• W4226371129 hasConcept C41008148 @default.
• W4226371129 hasConcept C44249647 @default.
• W4226371129 hasConcept C530470458 @default.
• W4226371129 hasConcept C71924100 @default.
• W4226371129 hasConcept C72563966 @default.

• next